Short answer: enclomiphene stimulates the body to make more of its own testosterone and can preserve sperm counts in ways exogenous TRT often does not — but it has no FDA approval of its own, so use for male hypogonadism or fertility preservation is off-label.
If you're researching options for low testosterone and want to preserve fertility, enclomiphene comes up quickly. It's often described as a "fertility-friendly" alternative to TRT — and mechanistically, that's accurate — but it's also a drug with a more complicated regulatory story than most marketing pages let on. Here's the science and the regulatory picture, in plain terms.
Where Enclomiphene Comes From
Enclomiphene citrate is one of two isomers that make up clomiphene citrate, a non-steroidal estrogen receptor antagonist — the other isomer, zuclomiphene, is separated out and not used.[3]Clomiphene itself has been FDA-approved since 1976, but only to treat female infertility. It's never been FDA-approved for use in men; when prescribed for male hypogonadism or infertility, it's used off-label.[1]
How It Actually Works
Enclomiphene is a selective estrogen receptor modulator, or SERM. It binds to estrogen receptors in the hypothalamus and blocks the signal estrogen normally sends there to suppress the release of gonadotropin-releasing hormone, or GnRH.[1] With that brake released, GnRH pulses more frequently, which prompts the pituitary gland to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH).[1]
That's the mechanistic difference that matters most: instead of supplying testosterone from an outside source, enclomiphene works upstream — it signals the testes to make more of a man's own testosterone, via LH acting on Leydig cells, while FSH continues supporting the Sertoli cell function sperm production depends on.[1]
Why Exogenous Testosterone Works Differently
Standard testosterone therapy raises blood testosterone directly, which triggers the same feedback loop in reverse. The hypothalamus and pituitary sense adequate or excess testosterone already circulating and respond by dialing back GnRH, LH, and FSH — which shuts down the body's own testosterone production and, as a direct consequence, impairs sperm production.[4] This is the core tradeoff that makes fertility preservation the main reason men consider enclomiphene over TRT in the first place.
What the Fertility Research Actually Shows
The most direct evidence comes from two parallel, randomized, double-blind, placebo-controlled Phase 3 trials that compared two doses of enclomiphene against topical testosterone gel (and placebo) in 256 overweight men aged 18–60 with secondary hypogonadism.[5] Both enclomiphene and testosterone gel raised total testosterone into the normal range by 16 weeks — but the two groups moved in opposite directions on LH and FSH. Those hormones rose in the enclomiphene groups and fell in the testosterone gel group, and while enclomiphene kept sperm concentrations in the normal range, testosterone gel caused a significant drop.[5]
Using a combined success measure — normal-range testosterone (300–1,040 ng/dL) plus a sperm concentration of at least 10 million/mL — pooled results across both trials showed success in 63.5% of men on enclomiphene, versus 24.7% on testosterone gel and 5.8% on placebo.[5]A separate, smaller study of 12 men who'd been on topical testosterone for at least six months found that switching to daily enclomiphene brought sperm counts up to a range of 75–334 million/mL (averaging 176 million/mL), meaningfully higher than while those same men were on testosterone.[1] A 2025 systematic review and meta-analysis of SERM therapy — pooling clomiphene and enclomiphene data — found significantly higher LH and FSH with SERM treatment compared to testosterone gel, comparable total testosterone outcomes between the two approaches, and no meaningful excess of adverse events with SERM therapy.[2]
Important regulatory context:Enclomiphene has never received its own FDA approval. Its original manufacturer submitted a New Drug Application under the brand name Androxal specifically for secondary hypogonadism, and the FDA didn't approve it — the agency's review found that raising testosterone levels alone wasn't sufficient evidence of efficacy for a non-testosterone hypogonadism therapy.[1] Because enclomiphene has no FDA-approved product of its own, and its parent compound is only approved for female ovulation induction, any use to treat male hypogonadism or preserve fertility is off-label by definition.[1]
The Bottom Line
Enclomiphene's fertility-preserving mechanism is real and backed by randomized trial data — the difference from testosterone therapy on sperm counts and LH/FSH is consistent and significant. What's equally real is that it's an off-label drug with no FDA approval of its own. That doesn't make it unsafe or illegitimate — off-label prescribing is common and legal — but it's a distinction worth understanding clearly before choosing it over TRT, especially since it isn't simply interchangeable with testosterone: it's mechanistically a different drug for a different priority.
If fertility preservation is a priority for you, it's worth asking any provider directly how they frame enclomiphene relative to standard TRT — then compare how different Men's Health providers handle labs and monitoring on RENVA's Men's Health / TRT hub or start with what TRT is actually proven to help with.
Sources
- Enclomiphene Citrate for the Treatment of Secondary Male Hypogonadism — PMC (National Institutes of Health) pmc.ncbi.nlm.nih.gov
- Clomiphene or enclomiphene citrate for the treatment of male functional hypogonadism — PMC (National Institutes of Health) pmc.ncbi.nlm.nih.gov
- Definition of enclomiphene citrate — National Cancer Institute Drug Dictionary, National Institutes of Health cancer.gov
- Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies — Translational Andrology and Urology (AME Publishing) tau.amegroups.org
- Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement — BJU International (Kim ED et al., via PubMed/NIH) pubmed.ncbi.nlm.nih.gov
Frequently Asked Questions
Is enclomiphene FDA-approved?
No. Enclomiphene has never received its own FDA approval, and its use for male hypogonadism or fertility preservation is off-label.[1]
Does enclomiphene actually preserve fertility better than TRT?
Randomized trial data shows enclomiphene maintained normal sperm concentrations while testosterone gel caused a significant drop, with a composite treatment-success rate of 63.5% for enclomiphene versus 24.7% for testosterone gel.[5]
Is enclomiphene the same thing as testosterone therapy?
No — they work through opposite mechanisms. Enclomiphene stimulates the body to produce more of its own testosterone, while TRT supplies testosterone directly from an outside source, which suppresses natural production.[1]
What is enclomiphene derived from?
It's one of two isomers in clomiphene citrate, a drug that's been FDA-approved for female infertility since 1976 but never approved for use in men.[3]